APA Style
Ruperto N, et al. ().
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials .
:
.
Chicago Style
Ruperto N, et al.
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
:
,
.
LITERATURE.
MLA Style
Ruperto N, et al.
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
:
,
.
LITERATURE.
Turabian Style
Ruperto N, et al.
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
:
,
.
LITERATURE.